更新于：2024-11-21

Acetaminophen

对乙酰氨基酚

更新于：2024-11-21

概要

概要

基本信息

简介对乙酰氨基酚是一种常见的用于镇痛和退热的OTC药物，于1951 年获得美国食品和药物管理局 (FDA) 的批准，它的作用方式与经典的非甾体抗炎药 (NSAID) 非常相似，通过阻碍 COX-1 和 COX-2 酶的活性发挥作用。对乙酰氨基酚用于治疗轻度至中度疼痛、中度至重度疼痛与阿片类药物联用，或对抗发烧。它是一种常见的治疗多种疾病的药物，例如头痛、肌肉酸痛、关节炎、背痛、牙痛、喉咙痛、感冒、流感和发烧。这种药物有多种剂型，包括糖浆、常规和泡腾剂片剂、注射剂和栓剂。虽然主要是口服给药，但也可以静脉内给药。重要的是过量服用对乙酰氨基酚是危险的，甚至可能是致命的。服用时必须遵循正确剂量，如果过量服用立即就医。对乙酰氨基酚于无需处方即可广泛使用处方药或作为处方药。

药物类型

小分子化药

别名

4'-hydroxyacetanilide、4-(Acetylamino)phenol、4-ACETAMIDOPHENOL

+ [89]

靶点

COX

作用机制

COX抑制剂(环氧化酶抑制剂)

治疗领域

神经系统疾病其他疾病

在研适应症

头痛镇痛发热+ [2]

非在研适应症

急性偏头痛麻醉普通感冒+ [19]

原研机构

丹东医创药业有限责任公司

在研机构

丹东医创药业有限责任公司

Fresenius Kabi USA LLC

Terumo Corp.

+ [13]

非在研机构

Merck Sharp & Dohme Corp.

Mallinckrodt Plc

Cosette Pharmaceuticals, Inc.初创企业

+ [14]

最高研发阶段批准上市

首次获批日期

中国 (1966-01-01),

发热疼痛

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构

分子式C8H9NO2

InChIKeyRZVAJINKPMORJF-UHFFFAOYSA-N

CAS号103-90-2

关联

1,413

项与对乙酰氨基酚相关的临床试验

NCT06689943 / Not yet recruiting临床2期IIT

Pain After Strabismus Surgery: Post-Operative Outcomes Using Courses of Acetaminophen in Children

At Ann & Robert H. Lurie Children's Hospital of Chicago (Lurie Children's), the current practice is to prescribe children with oral Tylenol as needed every 4-6 hours post strabismus surgery. Prescribing Tylenol "as needed" leaves more room for error for parents to be under-dosing their children, which can lead to avoidable pain. This study aims to figure out if children ages 4-12 years old will feel significantly less pain and discomfort when given regimented Tylenol every 6 hours for 48 hours after strabismus surgery (eye muscle surgery) compared to controls whose parents are instructed to give Tylenol every 4-6 hours as needed for 48 hours after surgery. To date, there have been no studies comparing patient outcomes between those taking Tylenol regimen and those receiving Tylenol as needed after pediatric surgery.

开始日期2025-01-01

申办/合作机构

Ann & Robert H. Lurie Children's Hospital of Chicago

NCT06671002 / Not yet recruiting临床4期IIT

Comparing Analgesic Regimen Effectiveness and Safety for Surgery for Kids (CARES for Kids) Trial

This trial is being completed to compare two commonly used options to treat pain after discharge from surgery. Participants that undergo tonsil removal, gallbladder removal, and knee scope will be eligible to enroll. Eligible participants will be randomized to prescription of 1 of 2 groups of medications (Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) plus acetaminophen or low dose opioids with the NSAIDs plus acetaminophen. The key question the study seeks to answer is which option will have the best outcomes and with the fewest side effects?

开始日期2025-01-01

申办/合作机构

University of Michigan

[+1]

NCT06653465 / Not yet recruiting临床2/3期IIT

Intravenous Acetaminophen for Postoperative Delirium in Older Patients Recovering From Major Noncardiac Surgery: a Randomised Controlled Study

Investigators propose this multi-center randomised controlled study to test the preventive effect of intravenouse acetaminophen in delirium over 5 postoperative days among older patients recovering from major non-cardiac surgery.

开始日期2024-12-01

申办/合作机构

上海交通大学医学院附属仁济医院

100 项与对乙酰氨基酚相关的临床结果

登录后查看更多信息

100 项与对乙酰氨基酚相关的转化医学

登录后查看更多信息

100 项与对乙酰氨基酚相关的专利（医药）

登录后查看更多信息

29,169

项与对乙酰氨基酚相关的文献（医药）

2025-01-01·Journal of Environmental Sciences

A review on reactive oxygen species-induced mechanism pathways of pharmaceutical waste degradation: Acetaminophen as a drug waste model

Review

作者: Hayyan, Maan ; Humayun, Saba ; Alias, Yatimah

Innately designed to induce physiological changes, pharmaceuticals are foreknowingly hazardous to the ecosystem. Advanced oxidation processes (AOPs) are recognized as a set of contemporary and highly efficient methods being used as a contrivance for the removal of pharmaceutical residues. Since reactive oxygen species (ROS) are formed in these processes to interact and contribute directly toward the oxidation of target contaminant(s), a profound insight regarding the mechanisms of ROS leading to the degradation of pharmaceuticals is fundamentally significant. The conceptualization of some specific reaction mechanisms allows the design of an effective and safe degradation process that can empirically reduce the environmental impact of the micropollutants. This review mainly deliberates the mechanistic reaction pathways for ROS-mediated degradation of pharmaceuticals often leading to complete mineralization, with a focus on acetaminophen as a drug waste model.

2025-01-01·Water Research

Reconsideration of the role of hydrogen peroxide in peroxymonocarbonate-based oxidation system for pollutant control

Article

作者: Zhou, Yi ; Zhao, Peiqing ; Jiang, Yiqian ; Yang, Zihan ; Meng, Xu

Advanced oxidation processes that utilize peroxymonocarbonate (HCO₄^-), generated in-situ through the reaction of HCO₃^- and H₂O₂, are employed for the removal of pollutants in water. Nevertheless, the precise role of H₂O₂ in these processes remains a subject of debate. This study established a HCO₄^--based oxidation system using NaHCO₃ and H₂O₂ for the degradation of acetaminophen and investigated the activation mechanisms of coexisting oxidants. Under thermal activation conditions, the OO bond in HCO₄^- (HOOCOO^-) was more readily cleaved than the OO bond in the co-existing oxidant H₂O₂ (HOOH), leading to the generation of reactive oxygen species (ROS). Based on kinetics and ROS evaluation, H₂O₂ primarily served to form HCO₄^- rather than converting to ·OH or O₂, with HCO₄^- acting as the primary oxidant for degradation through the formation of CO₃^·-and ·OH. In this oxidation system, H₂O₂ utilization efficiency for ·OH production reached 27.34 %, ·OH yield reached 24.15 % and acetaminophen degradation efficiency realized 83 % at 60 °C with 20 mM HCO₃^- and 20 mM H₂O₂. The apparent activation energy of acetaminophen degradation and HCO₄^- activation were calculated as 90.83 kJ mol^-1 and 18.81 kJ mol^-1, respectively. Moreover, a novel CO₂-derived HCO₄^--based system led to a comparable acetaminophen degradation efficiency of 82 % and a higher k_obs of 0.028 min^-1. The system optimization and ROS evaluation suggest that high concentration of H₂O₂ inhibited the degradation and quenched CO₃^·- and ·OH to yield ·O₂^- and ¹O₂. Furthermore, EPR analysis and quenching experiments indicate that CO₃^·- was mainly responsible for acetaminophen degradation. This work provides fundamental understanding of the HCO₄^--based oxidation system.

2025-01-01·Water Research

Quality evaluation parameter and classification model for effluents of wastewater treatment plant based on machine learning

Article

作者: Ren, Hongqiang ; Wu, Bing ; Chen, Ling ; Zhu, Mengyuan ; Mu, Hongxin ; He, Ruonan ; Wang, Jiawei

With the growing consensus of emerging pollutants and biological toxicity risks in wastewater treatment plant (WWTP) effluents, traditional water quality management based on general chemical parameters no longer meets the new challenges. Here, a first-hand dataset containing 9 conventional parameters, 22 mental and inorganic ions, 25 biotoxicity parameters, and 54 emerging pollutants from effluents of 176 municipal WWTPs across China were measured. Four clustering algorithms and five classification algorithms were applied to 65 well-performing models to determine a novel evaluation parameter system. A total of 14 parameters were selected by semi-supervised machine learning, including TN, TP, NH₄⁺-N, NO₂^--N, Se, SO₄^2-, Caenorhabditis elegans body width, 72 hpf zebrafish embryo hatching rate, tetracycline, acetaminophen, gemfibrozil (Lopid), PFBA, PFHxA, and HFPO-DA. These parameters were then used to construct a Healthy Effluent Quality Index model (HEQi). The application efficiency of HEQi was compared with other common methods such as the Water Quality Index (WQI), Fuzzy Synthesized Evaluation (FSE), and Technique for Order Preference by Similarity to Ideal Solution (TOPSIS) in classifying 176 effluents. Results implicated that under the new evaluation criteria, the major task in North and Northeast China remains to reduce the conventional parameters, especially NO₂^--N. However, it is necessary to strengthen the removal of biotoxicity and emerging pollutants in parts of Central and Eastern China. This study offers new methodological tools and scientific insights for improving water quality assessment and safe discharge of wastewater.

725

项与对乙酰氨基酚相关的新闻（医药）

2024-11-18

·drugs

Climate Change to Blame for Almost 1 in 5 New Dengue Infections

MONDAY, Nov. 18, 2024 -- One in five cases of dengue fever can be linked to climate change, and future surges in the mosquito-borne virus are inevitable, a new study says. About 19% of current dengue cases can be tied to climate change, which has expanded the area within which mosquitos transmit disease both in the United States and around the world, researchers report. Even worse, climate change has the potential to spark a 40% to 60% spike in the disease by 2050, with cases increasing much as 150% to 200% in some areas. “As more and more of the U.S. moves into that optimal temperature range for dengue, the number of locally acquired infections will likely rise, though it’s too early to say how that will affect the global burden,” said senior researcher Erin Mordecai , an infectious disease ecologist at Stanford University in California. Mosquitos that carry dengue progressively churn out more and more virus as temperatures rise into a specific range, from 68 degrees Fahrenheit to around 82 degrees, lab tests have shown. Regions around the world will face an increased risk from the virus as their temperatures reach that dengue “sweet spot,” researchers reported Saturday at the annual meeting of the American Society of Tropical Medicine and Hygiene in New Orleans. Overall, there are at least 257 million people living in places where climate warming could cause dengue cases to double in the next 25 years, researchers concluded. The most common symptoms of dengue fever are aches and pains, nausea, vomiting and rash. More severe cases cause excruciating joint pain, earning dengue the nickname “breakbone fever,” as well as bleeding complications and shock, researchers said. There are no specific medicines to treat dengue. Instead, people are told to rest, drink plenty of fluids and take acetaminophen to control fever and pain, according to the U.S. Centers for Disease Control and Prevention. A dengue vaccine is available in the United States for children ages 9 to 16 who’ve already had a dengue infection and live in areas where dengue is common, the CDC says. For the new study, researchers analyzed data on dengue cases and climate variation across 21 countries in Asia, North America and South America. They found that countries in the Americas alone have recorded nearly 12 million cases of dengue in 2024, compared to 4.6 million in 2023. California and Florida have both reported locally acquired infections of dengue. “Climate change already has become a significant threat to human health and, for dengue in particular, our data suggests the impact could get much worse,” Mordecai said in a Stanford news release. The researchers’ analysis showed that sharp cuts in greenhouse gas emissions could blunt a projected 60% increase in cases by 2050 to just 40%. However, 17 of the 21 countries studied will still see climate-driven increases in dengue even under the most optimistic scenarios, researchers say. Places where dengue is already established as a transmissible disease -- including parts of Peru, Mexico, Bolivia and Brazil -- could face the biggest increases, with infections rising 150% to 200% during the next few decades. These findings likely underestimate the risk of dengue caused by climate change, Mordecai added. That’s because many places that could be affected don’t consistently track dengue infections, such as large parts of sub-Saharan Africa and South Asia. Researchers also were unable to quantify future impacts for areas like the U.S. south, where dengue is starting to emerge as a local threat, Mordecai said. Because these findings were presented at a medical meeting, they should be considered preliminary until published in a peer-reviewed journal. Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

疫苗

2024-11-17

·药筛

江苏华阳比拉斯汀片首仿获批，妥布霉素滴眼液新增两家过评 | 仿制药周报（11.11-11.17）

统计每周仿制药一致性评价申报、上市申请（11.11-11.17） 1、仿制药上市申请获批药品名称企业名称分类受理号阿立哌唑片海正药业（杭州）有限公司;瀚晖制药有限公司4CYHS2301744阿立哌唑片海正药业（杭州）有限公司;瀚晖制药有限公司4CYHS2301743阿立哌唑片重庆药友制药有限责任公司4CYHS2301745艾考糊精腹膜透析液青岛力腾医药科技有限公司;上海长征富民金山制药有限公司4CYHS2303165奥硝唑注射液江苏正大清江制药有限公司3CYHS2300531奥硝唑注射液江苏正大清江制药有限公司3CYHS2300530比拉斯汀片江苏华阳制药有限公司4CYHS2301854达格列净片北京伟林恒昌医药科技有限公司;北京京丰制药集团有限公司4CYHS2301011达格列净片北京伟林恒昌医药科技有限公司;北京京丰制药集团有限公司4CYHS2301010地高辛注射液成都瑞尔医药科技有限公司;四川美大康佳乐药业有限公司3CYHS2301354丁二磺酸腺苷蛋氨酸肠溶片浙江普洛康裕制药有限公司4CYHS2300471二甲双胍恩格列净片(Ⅲ)浙江诺得药业有限公司4CYHS2400014二羟丙茶碱注射液江苏瑜兴医药科技有限公司;亚邦医药股份有限公司3CYHS2301642法莫替丁注射液济川药业集团有限公司;太极集团四川太极制药有限公司3CYHS2301461法莫替丁注射液山西威奇达光明制药有限公司3CYHS2301277非布司他片河北爱普制药有限公司4CYHS2302292非布司他片河北爱普制药有限公司4CYHS2302291非布司他片山东淄博新达制药有限公司4CYHS2301652非布司他片涿州东乐制药有限公司4CYHS2301486夫西地酸乳膏华东医药（西安）博华制药有限公司4CYHS2301389呋塞米口服溶液北京诚济制药股份有限公司3CYHS2300293复方氨基酸（16）双肽（1）注射液内蒙古白医制药股份有限公司3CYHS2400802复方氨基酸（16）双肽（1）注射液内蒙古白医制药股份有限公司3CYHS2400801复方电解质注射液昆明南疆制药有限公司4CYHS2302049枸橼酸西地那非口崩片云南龙津康佑生物医药有限公司;昆明龙津药业股份有限公司4CYHS2302088甲泼尼龙片濮阳市汇元药业有限公司4CYHS2301694聚乙烯醇滴眼液吉林敖东药业集团延吉股份有限公司4CYHS2400435聚乙烯醇滴眼液浙江恒研医药科技有限公司;浙江赛默制药有限公司3CYHS2300898拉考沙胺注射液常州四药制药有限公司4CYHS2301646利格列汀二甲双胍片（Ⅱ）浙江华海药业股份有限公司4CYHS2301820利奈唑胺葡萄糖注射液Nang Kuang Pharmaceutical Co., Ltd5.2JYHS2101000磷酸奥司他韦胶囊海南葫芦娃药业集团股份有限公司4CYHS2301713氯化钾注射液辽宁民康制药有限公司;湖南科伦制药有限公司3CYHS2301778氯雷他定糖浆黑龙江中桂制药有限公司4CYHS2300864氯雷他定糖浆黑龙江中桂制药有限公司4CYHS2300863马来酸阿伐曲泊帕片四川科伦药业股份有限公司4CYHS2302433蒙脱石散浙江爱生药业有限公司4CYHS2300938蒙脱石散福建太平洋制药有限公司4CYHS2300229孟鲁司特钠片河南比福制药股份有限公司4CYHS2301573哌柏西利胶囊江西半边天药业有限公司;重庆西南制药二厂有限责任公司4CYHS2300712哌柏西利胶囊江西半边天药业有限公司;重庆西南制药二厂有限责任公司4CYHS2300713哌柏西利胶囊江西半边天药业有限公司;重庆西南制药二厂有限责任公司4CYHS2300711普拉洛芬滴眼液宏越科技（湖州）有限公司;江西科伦药业有限公司4CYHS2301273普瑞巴林缓释片浙江诺得药业有限公司3CYHS2303406普瑞巴林缓释片浙江诺得药业有限公司3CYHS2303405乳果糖口服溶液华萃国际生物科技（广东）有限公司;太极集团四川太极制药有限公司4CYHS2301081乳果糖口服溶液华萃国际生物科技（广东）有限公司;太极集团四川太极制药有限公司4CYHS2301080乳果糖口服溶液河北智恒医药科技股份有限公司;葵花药业集团（冀州）有限公司4CYHS2300784乳果糖口服溶液海南万玮制药有限公司4CYHS2300766乳果糖口服溶液江右制药（常德）有限公司;四川先通药业有限责任公司4CYHS2202081瑞戈非尼片重庆药友制药有限责任公司4CYHS2300602舒更葡糖钠注射液吉林省博大伟业制药有限公司4CYHS2301302他达拉非片四川依科制药有限公司4CYHS2302218酮咯酸氨丁三醇注射液重庆莱美药业股份有限公司3CYHS2303574妥布霉素滴眼液浙江莎普爱思药业股份有限公司4CYHS2302059妥布霉素滴眼液苏州乐珠制药有限公司4CYHS2300911维生素B12滴眼液中山万汉制药有限公司4CYHS2303248盐酸阿罗洛尔片山东中健康桥制药有限公司4CYHS2201373盐酸氨溴索滴剂山东京卫制药有限公司3CYHS2300993盐酸奥洛他定滴眼液沈阳兴齐眼药股份有限公司4CYHS2301887盐酸甲氧氯普胺注射液浙江百代医药科技有限公司;浙江赛默制药有限公司3CYHS2301038乙酰半胱氨酸颗粒哈尔滨华瑞生化药业有限责任公司;海南海神同洲制药有限公司4CYHS2301907注射用哌拉西林钠他唑巴坦钠浙江众延医药科技有限公司;江苏海宏制药有限公司4CYHS2300701注射用哌拉西林钠他唑巴坦钠浙江众延医药科技有限公司;江苏海宏制药有限公司4CYHS2300700注射用培美曲塞二钠仁合熙德隆药业有限公司4CYHS2301520注射用培美曲塞二钠仁合熙德隆药业有限公司4CYHS2301519注射用培美曲塞二钠瑞迪博士（北京）药业有限公司;河北道恩药业有限公司4CYHS2300430注射用培美曲塞二钠瑞迪博士（北京）药业有限公司;河北道恩药业有限公司4CYHS2300429注射用头孢哌酮钠舒巴坦钠山东晶辉生物技术有限公司;山东润泽制药有限公司4CYHS2403186注射用头孢哌酮钠舒巴坦钠山东晶辉生物技术有限公司;山东润泽制药有限公司4CYHS2403184注射用头孢哌酮钠舒巴坦钠山东晶辉生物技术有限公司;山东润泽制药有限公司4CYHS2403187注射用头孢哌酮钠舒巴坦钠山东晶辉生物技术有限公司;山东润泽制药有限公司4CYHS2403183注射用头孢哌酮钠舒巴坦钠山东晶辉生物技术有限公司;山东润泽制药有限公司4CYHS2403182注射用头孢哌酮钠舒巴坦钠山东晶辉生物技术有限公司;山东润泽制药有限公司4CYHS2403190注射用头孢唑肟钠海南合瑞制药股份有限公司4CYHS2302264注射用头孢唑肟钠海南合瑞制药股份有限公司4CYHS2302263注射用头孢唑肟钠重庆药谷制药有限公司;重庆科瑞制药（集团）有限公司4CYHS2302069注射用头孢唑肟钠重庆药谷制药有限公司;重庆科瑞制药（集团）有限公司4CYHS2302068注射用头孢唑肟钠山东如至生物医药科技有限公司;沈阳三九药业有限公司4CYHS2301956注射用头孢唑肟钠山东如至生物医药科技有限公司;沈阳三九药业有限公司4CYHS2301957注射用头孢唑肟钠重庆吉斯瑞制药有限责任公司4CYHS2301542注射用盐酸罗沙替丁醋酸酯合肥昊益医药科技有限公司;海南合瑞制药股份有限公司3CYHS2301255左甲状腺素钠片Cipla Ltd.;M/s Acme Generics Pvt. Ltd.5.2JYHS2300065左甲状腺素钠片Cipla Ltd.;M/s Acme Generics Pvt. Ltd.5.2JYHS2300066 注：灰色字体部分受理号结论为不批准。 2、一致性评补充申请获批药品名称企业名称受理号醋酸地塞米松片新乡市常乐制药有限责任公司CYHB2450090呋塞米注射液遂成药业股份有限公司CYHB2350671复方氯化钠注射液湖南科伦制药有限公司CYHB1850399复方匹可硫酸钠颗粒辉凌制药（中国）有限公司CYHB2350628氯化钾注射液四川美大康华康药业有限公司;山东华鲁制药有限公司CYHB2450007盐酸艾司洛尔注射液山东鲁抗医药集团赛特有限责任公司CYHB2350666盐酸氨基葡萄糖片四川新斯顿制药股份有限公司CYHB2050175盐酸氯丙嗪片万邦德制药集团有限公司CYHB2250526盐酸普萘洛尔注射液重庆药友制药有限责任公司CYHB2450148盐酸普萘洛尔注射液重庆药友制药有限责任公司CYHB2450149乙酰半胱氨酸颗粒广东百澳药业有限公司CYHB2350596注射用苯唑西林钠瑞阳制药股份有限公司;山东二叶制药有限公司CYHB2350656注射用苯唑西林钠瑞阳制药股份有限公司;山东二叶制药有限公司CYHB2350657注射用头孢呋辛钠珠海联邦制药股份有限公司中山分公司CYHB2350904注射用头孢呋辛钠珠海联邦制药股份有限公司中山分公司CYHB2350905注射用头孢呋辛钠海南海灵化学制药有限公司CYHB2350894注射用头孢呋辛钠海南海灵化学制药有限公司CYHB2350893注射用头孢西丁钠苏州二叶制药有限公司CYHB2350778注射用头孢西丁钠苏州二叶制药有限公司CYHB2350779注射用头孢西丁钠海南通用三洋药业有限公司CYHB2350550注射用头孢西丁钠海南通用三洋药业有限公司CYHB2350551注射用头孢唑林钠苏州东瑞制药有限公司CYHB2350531注射用头孢唑肟钠苏州中化药品工业有限公司CYHB2450008注射用头孢唑肟钠苏州中化药品工业有限公司CYHB2450009注射用头孢唑肟钠苏州二叶制药有限公司CYHB2350884注射用头孢唑肟钠苏州二叶制药有限公司CYHB2350882注射用左亚叶酸钙齐鲁制药有限公司CYHB2350852注射用左亚叶酸钙齐鲁制药有限公司CYHB2350851 注：灰色字体部分受理号结论为不批准。 3、新增仿制药上市申请药品名称企业名称分类受理号阿达帕林凝胶浙江康恩贝制药股份有限公司4CYHS2403888阿达帕林凝胶浙江普利药业有限公司4CYHS2403860阿帕他胺片南京正大天晴制药有限公司4CYHS2403947阿昔莫司胶囊江苏谦仁生物科技有限公司4CYHS2403890比索洛尔氨氯地平片宁波科尔康美诺华药业有限公司;宁波美诺华天康药业有限公司4CYHS2403884比索洛尔氨氯地平片江苏万高药业股份有限公司4CYHS2403889丙酸氟替卡松雾化吸入用混悬液浙江高跖医药科技股份有限公司;浙江赛默制药有限公司4CYHS2403948醋氯芬酸片广东迈恒医药研发有限公司;浙江赛默制药有限公司3CYHS2403858醋酸艾替班特注射液远大医药（中国）有限公司4CYHS2403873碘佛醇注射液海南倍康医药科技有限公司;成都倍特药业股份有限公司4CYHS2403929恩格列净二甲双胍缓释片江苏谦仁生物科技有限公司3CYHS2403928二甲硅油乳剂江苏盈科生物制药有限公司4CYHS2403852法莫替丁注射液武汉天安医药科技有限公司;山西威奇达光明制药有限公司3CYHS2403872非布司他片白云山东泰商丘药业有限公司4CYHS2403940非布司他片白云山东泰商丘药业有限公司4CYHS2403939酚咖片北京诚济制药股份有限公司3CYHS2403871氟维司群注射液湖州亚瑟制药有限公司4CYHS2403924复方聚乙二醇电解质散（Ⅲ）湖北潜龙药业有限公司4CYHS2403914复方维生素C聚乙二醇（3350）钠钾散湖北莱康医疗技术有限公司;广东华南药业集团有限公司3CYHS2403878富马酸福莫特罗吸入溶液江苏大红鹰恒顺药业有限公司4CYHS2403891琥珀酸亚铁片江苏万高药业股份有限公司3CYHS2403926己酮可可碱注射液上海现代哈森（商丘）药业有限公司3CYHS2403851聚乙烯醇滴眼液苏州乐珠制药有限公司4CYHS2403847克立硼罗软膏北京福元医药股份有限公司;福元药业有限公司4CYHS2403848拉莫三嗪片南京海鲸药业股份有限公司4CYHS2403885拉莫三嗪片南京海鲸药业股份有限公司4CYHS2403886雷米普利片浙江华海制药科技有限公司4CYHS2403944雷米普利片浙江华海制药科技有限公司4CYHS2403945利丙双卡因乳膏四川合纵泽辉医药科技有限公司;江苏知原药业股份有限公司4CYHS2403918磷酸芦可替尼片杭州中美华东制药有限公司4CYHS2403941硫酸氨基葡萄糖胶囊浙江领创优品药业有限公司;浙江赛默制药有限公司4CYHS2403946硫酸氨基葡萄糖胶囊湖北泰林医药有限公司;浙江赛默制药有限公司4CYHS2403902硫酸氨基葡萄糖胶囊苏州第四制药厂有限公司4CYHS2403877硫酸特布他林雾化吸入用溶液湖南醇健制药科技有限公司;浙江赛默制药有限公司4CYHS2403895硫辛酸片山东鲁宁药业有限公司3CYHS2403893硫辛酸片山东鲁宁药业有限公司3CYHS2403894硫辛酸注射液浙江昂利康制药股份有限公司;浙江赛默制药有限公司4CYHS2403866硫辛酸注射液浙江昂利康制药股份有限公司;浙江赛默制药有限公司4CYHS2403865氯化钾口服溶液河南华雒康润药业有限公司3CYHS2403868洛索洛芬钠口服溶液合肥启旸生物医药科技有限公司;合肥华威药业有限公司3CYHS2403938门冬氨酸钾镁注射液海南全星制药有限公司3CYHS2403855门冬氨酸钾注射液山东齐都药业有限公司3CYHS2403844钠钾镁钙注射用浓溶液海西新药创制（福州）有限公司;福安药业集团宁波天衡制药有限公司3CYHS2403923钠钾镁钙注射用浓溶液广州大光制药有限公司;湖南科伦制药有限公司3CYHS2403861钠钾镁钙注射用浓溶液安徽双鹤药业有限责任公司3CYHS2403856尼麦角林片浙江恒研医药科技有限公司;浙江赛默制药有限公司3CYHS2403846尼麦角林片浙江恒研医药科技有限公司;浙江赛默制药有限公司3CYHS2403845普瑞巴林口服溶液盖天力医药控股集团制药股份有限公司;江苏欧歌制药有限公司3CYHS2403917普瑞巴林口服溶液盖天力医药控股集团制药股份有限公司;江苏欧歌制药有限公司3CYHS2403916普瑞巴林口服溶液盖天力医药控股集团制药股份有限公司;江苏欧歌制药有限公司3CYHS2403915噻托溴铵吸入粉雾剂苏州欧米尼医药有限公司4CYHS2403887沙格列汀二甲双胍缓释片（Ⅰ）江苏永安制药有限公司4CYHS2403931沙库巴曲缬沙坦钠片湖南天济草堂制药股份有限公司4CYHS2403869沙库巴曲缬沙坦钠片湖南天济草堂制药股份有限公司4CYHS2403870碳酸氢钠血滤置换液宁波泰瑞斯科技有限公司4CYHS2403933碳酸氢钠注射液北京民康百草医药科技有限公司;武汉福星生物药业有限公司3CYHS2403899酮咯酸氨丁三醇片山东朗诺制药有限公司3CYHS2403892妥布霉素滴眼液浙江国光生物制药股份有限公司;杭州国光药业股份有限公司4CYHS2403930妥布霉素滴眼液江苏广承药业有限公司4CYHS2403932维生素B6注射液康普药业股份有限公司3CYHS2403905乌帕替尼缓释片江苏华阳制药有限公司4CYHS2403925西格列汀二甲双胍片（Ⅰ）石家庄市华新药业有限责任公司4CYHS2403921西格列汀二甲双胍片（Ⅰ）石家庄市普力制药有限公司4CYHS2403874西格列汀二甲双胍片（Ⅱ）石家庄市华新药业有限责任公司4CYHS2403922西格列汀二甲双胍片（Ⅱ）石家庄市普力制药有限公司4CYHS2403875西甲硅油乳剂广西维威制药有限公司;四川先通药业有限责任公司4CYHS2403927西尼地平片湖南普道医药技术有限公司;湖南九典制药股份有限公司3CYHS2403862腺苷注射液安徽长江药业有限公司4CYHS2403906盐酸阿莫罗芬搽剂合肥启旸生物医药科技有限公司;合肥华威药业有限公司4CYHS2403920盐酸氨溴索口服溶液湖北唯森制药有限公司4CYHS2403937盐酸奥布卡因滴眼液江苏瑜兴医药科技有限公司;江苏大红鹰恒顺药业有限公司4CYHS2403943盐酸氟西汀口服溶液安徽四环科宝制药有限公司3CYHS2403882盐酸氟西汀口服溶液安徽四环科宝制药有限公司3CYHS2403881盐酸氟西汀口服溶液安徽四环科宝制药有限公司3CYHS2403883盐酸氟西汀口服溶液安徽四环科宝制药有限公司3CYHS2403880盐酸甲氧氯普胺注射液重庆天致药业股份有限公司;河南天致药业有限公司3CYHS2403936盐酸莫西沙星片重庆世森医药科技有限公司;兰西哈三联制药有限公司4CYHS2403863盐酸普萘洛尔注射液石家庄四药有限公司3CYHS2403897盐酸普萘洛尔注射液石家庄四药有限公司3CYHS2403896盐酸普萘洛尔注射液江西人可医药科技有限公司;津药和平（天津）制药有限公司3CYHS2403854盐酸普萘洛尔注射液江西人可医药科技有限公司;津药和平（天津）制药有限公司3CYHS2403853盐酸沙丙蝶呤散剂Annora Pharma Private Limited5.2JYHS2400056盐酸沙丙蝶呤散剂Annora Pharma Private Limited5.2JYHS2400055乙酰半胱氨酸颗粒海南广升誉制药有限公司;江苏诚康药业有限公司4CYHS2403912乙酰半胱氨酸颗粒海南广升誉制药有限公司;江苏诚康药业有限公司4CYHS2403913乙酰半胱氨酸片杭州沐源生物医药科技有限公司;成都通德药业有限公司3CYHS2403857异丙托溴铵吸入气雾剂四川普锐特药业有限公司4CYHS2403876注射用厄他培南海南倍特药业有限公司4CYHS2403919注射用拉氧头孢钠海南倍特药业有限公司3CYHS2403909注射用拉氧头孢钠海南倍特药业有限公司3CYHS2403908注射用硫酸艾沙康唑四川美大康华康药业有限公司4CYHS2403907注射用硫酸艾沙康唑海南皇隆制药股份有限公司4CYHS2403879注射用氯诺昔康浙江尖峰药业有限公司4CYHS2403867注射用哌拉西林钠江苏睿实生物科技有限公司;四川制药制剂有限公司3CYHS2403935注射用哌拉西林钠江苏睿实生物科技有限公司;四川制药制剂有限公司3CYHS2403934注射用硼替佐米山东新时代药业有限公司4CYHS2403910注射用硼替佐米山东新时代药业有限公司4CYHS2403911注射用头孢呋辛钠安徽杰玺医药有限公司;沈阳三九药业有限公司4CYHS2403904注射用头孢呋辛钠安徽杰玺医药有限公司;沈阳三九药业有限公司4CYHS2403903注射用头孢美唑钠安徽杰玺医药有限公司;沈阳三九药业有限公司3CYHS2403900注射用头孢美唑钠安徽杰玺医药有限公司;沈阳三九药业有限公司3CYHS2403901注射用头孢他啶/氯化钠注射液北京锐业制药（潜山）有限公司4CYHS2403850注射用头孢他啶/氯化钠注射液北京锐业制药（潜山）有限公司4CYHS2403849注射用盐酸万古霉素安徽省先锋制药有限公司4CYHS2403859左卡尼汀口服溶液云南海沣药业有限公司4CYHS2403942唑来膦酸注射液浙江康吉尔药业有限公司4CYHS2403898 4、新增一致性评价补充申报药品名称企业名称受理号地高辛注射液上海禾丰制药有限公司CYHB2450565地塞米松磷酸钠注射液郑州卓峰制药有限公司CYHB2450562对乙酰氨基酚颗粒苏州中化药品工业有限公司CYHB2450567维生素B6注射液浙江瑞新药业股份有限公司CYHB2450564注射用更昔洛韦上海华源药业（宁夏）沙赛制药有限公司CYHB2450566注射用赖氨匹林四川美大康华康药业有限公司CYHB2450563 数据来源：摩熵医药相关阅读：山东鲁盛多种维生素(12)获批上市，成都苑东甲磺酸萘莫司他上市申请 | 仿制药周报（11.4-11.10）黄体酮阴道缓释凝胶仿制申请全被否，伏诺拉生片新增3家仿制申请 | 仿制药周报（10.28-11.3）四川汇宇乙酰半胱氨酸注射液首家过评，南京海纳酮洛芬凝胶贴膏上市申请 | 仿制药周报（10.21-10.27）正大天晴来特莫韦首仿获批，石家庄科仁艾普拉唑肠溶片第2家仿制申请 | 仿制药周报（10.14-10.20）

一致性评价上市批准

2024-11-14

·PRNewswire

CureLab Oncology Seeks to Revolutionize Chronic Pain Management with Novel p62-Based Therapy

Patent application paves the way for a potential breakthrough in chronic pain treatment, offering renewed hope for millions BOSTON, Nov. 14, 2024 /PRNewswire/ -- CureLab Oncology, a clinical-stage biotech company dedicated to pioneering innovative therapies, announced a patent application for an innovative chronic pain treatment centered on its p62/SQSTM1 DNA plasmid. This development, which leverages CureLab's chronic inflammation therapeutic, Elenagen™, signifies a potential paradigm shift in addressing chronic pain, a pervasive health challenge that affects millions globally. Continue Reading With this patent, CureLab Oncology positions its lead therapeutic, Elenagen™, to address the limitations of existing chronic pain treatments, such as NSAIDs (nonsteroidal anti-inflammatory drugs), acetaminophen, COX-2 inhibitors, antidepressants, anti-seizure medications, and opioids. With this patent, CureLab Oncology aims to address the limitations of existing chronic pain treatments, such as NSAIDs (nonsteroidal anti-inflammatory drugs), acetaminophen, COX-2 inhibitors, antidepressants, anti-seizure medications, and opioids. While these medications offer varying degrees of pain relief, they often come with a range of side effects, including gastrointestinal problems, kidney problems, stomach bleeding, ulcers, dizziness, drowsiness, nausea, and potential addiction. The patent emphasizes the urgent need for more effective chronic pain medications with fewer side effects. The patent application encompasses the utilization of p62/SQSTM1 DNA to combat a wide spectrum of chronic pain conditions, including arthritis, back pain, headaches, cancer pain, neuropathic pain, and fibromyalgia. This therapeutic strategy operates by modulating the body's inflammatory response, a critical factor in the development and persistence of chronic pain. "Chronic pain often stems from persistent inflammation, a complex biological response that can disrupt the body's natural healing processes," explained Dr. Alexander Shneider, CEO of CureLab Oncology. "Elenagen, our innovative p62-based therapy, targets this underlying inflammation, promoting resolution and potentially alleviating pain at its source." This groundbreaking therapy holds immense promise for both humans and animals suffering from chronic pain. Preclinical investigations employing animal models have illuminated the efficacy of this therapy in mitigating pain severity and augmenting the quality of life. Notably, the therapy exhibits a favorable safety profile, with no substantial adverse effects detected in the studies. The global chronic pain treatment market is expected to reach $131.4 billion by 2030, growing at a compound annual growth rate (CAGR) of 4.3% from 2023 to 2030. This growth is driven by the increasing prevalence of chronic pain, the aging population, and the rising demand for effective and non-addictive pain management options. With its potential for fewer side effects and broader applications compared to current treatments, CureLab's p62-based therapy is positioned to meet the growing demand of the growing chronic pain market. "Our patenting strategy for this chronic pain treatment aligns with our successful approach for other therapies," said Ilya Lapshin, general counsel for CureLab Oncology. "By initially filing a provisional patent application in the USA and subsequently seeking worldwide protection, we aim to secure comprehensive intellectual property rights for this groundbreaking innovation." To see CureLab's portfolio of patents, visit curelaboncology.com/ip and curelabveterinary.com/ip. About Elenagen CureLab's lead investigational compound is code-named Elenagen, an experimental DNA therapy that consists of a circular piece of DNA called a plasmid that includes a gene for a human protein called p62/SQSTM1. In clinical studies conducted ex-US, Elenagen demonstrated desirable safety profile and statistically significant clinical benefit for cancer patients enhancing the anti-cancer effects of chemotherapy. Experimental results also demonstrate mitigation of chronic inflammation, anti-aging effects, and stimulation of an immune response to the tumor. About CureLab Oncology CureLab Oncology Inc. is a pre-IPO, clinical-stage biotech company headquartered in the greater Boston area, Massachusetts. CureLab is dedicated to advancing new and safer therapeutics for solid tumors and other oncology and inflammatory indications. To learn more, visit curelab.com. Media contact: Tim Cox, ZingPR, [email protected] SOURCE CureLab Oncology Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

100 项与对乙酰氨基酚相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00217	对乙酰氨基酚	N02BE01	DB00316

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
头痛	美国	Taro Pharmaceutical Industries Ltd.	1980-04-22
镇痛	日本	Iwaki Seiyaku Co., Ltd.	1966-07-01
发热	中国	丹东医创药业有限责任公司	1966-01-01
疼痛	中国	丹东医创药业有限责任公司	1966-01-01

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
疼痛	临床2期	美国	MALLINCKRODT HOSP PRODUCTS IP LTD	2010-11-02
糖尿病性神经病变	临床2期	-	Johnson & Johnson Pharmaceutical Research & Development LLC	2003-12-01
术后疼痛	临床2期	-	Merck Sharp & Dohme Corp.	2002-06-01
牙痛	临床2期	-	Merck Sharp & Dohme Corp.	2002-06-01
膝关节炎	临床2期	-	Johnson & Johnson Holdco (NA), Inc.	1999-10-01
发热	临床2期	美国	Cosette Pharmaceuticals, Inc.初创企业	1978-02-09
头痛	临床2期	美国	Cosette Pharmaceuticals, Inc.初创企业	1978-02-09

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04291508 (ASTER, CTgov)	临床2期	呼吸衰竭 \| 危重病 \| 脓毒症 \| 急性呼吸窘迫综合征	488	Intravenous Acetaminophen (room temperature) (IV Acetaminophen-Active)	範壓網鑰範顧壓蓋夢網(艱鑰廠築遞壓齋構艱襯) = 餘夢襯鹹襯艱選憲艱鹽鬱製窪鹽窪醖遞憲簾顧 (淵糧鹹構憲製鬱獵築糧, 積醖獵鹹憲鏇構醖願願 ~ 觸構艱鹽齋齋網鹹糧獵) 更多	-	2024-09-27
				Intravenous Vitamin C (refrigerated) (IV Vitamin C-Active)	範壓網鑰範顧壓蓋夢網(艱鑰廠築遞壓齋構艱襯) = 繭淵艱選醖鏇獵鬱遞壓鬱製窪鹽窪醖遞憲簾顧 (淵糧鹹構憲製鬱獵築糧, 顧鏇鬱襯繭廠選選衊鏇 ~ 夢齋網鹽製衊糧鏇簾繭) 更多
NCT03859024 (CTgov)	临床4期	尿道狭窄 \| 术后疼痛	48	Acetaminophen+Ibuprofen 800 mg+Oxycodone (Standard Protocol)	夢壓醖窪鏇糧襯積網簾(廠選遞願繭鏇膚選構願) = 廠網獵築築衊鹽鹽選構糧觸遞觸鏇簾願廠鏇壓 (鬱鹹艱鬱簾製餘鏇糧網, 襯壓獵鹹憲醖鬱糧選衊 ~ 鬱廠憲顧鬱鏇簾餘製範) 更多	-	2024-09-19
				Acetaminophen+Ibuprofen 800 mg+celebrex+Dexamethasone+Oxycodone+Bupivacaine+Gabapentin (Enhanced Recovery Protocol)	夢壓醖窪鏇糧襯積網簾(廠選遞願繭鏇膚選構願) = 鬱獵夢構壓膚膚廠醖鏇糧觸遞觸鏇簾願廠鏇壓 (鬱鹹艱鬱簾製餘鏇糧網, 餘觸繭構夢襯糧襯鏇顧 ~ 網繭廠觸窪廠齋觸製鹹) 更多
NCT04879823 (CTgov)	临床3期	镇痛	222	Acetaminophen+Ibuprofen+Dexamethasone (Dexamethasone)	製鬱醖淵獵鬱夢衊鏇遞(網鬱鬱遞艱憲願觸襯膚) = 廠鑰廠鹽夢窪鏇壓繭遞積鑰憲獵鹽鹹齋衊憲餘 (蓋憲築淵壓鬱選襯鏇窪, 窪膚襯顧膚鑰顧觸範鹽 ~ 積鹹積鏇顧遞蓋遞醖繭) 更多	-	2024-09-05
				Placebo+Acetaminophen+Ibuprofen (Placebo)	製鬱醖淵獵鬱夢衊鏇遞(網鬱鬱遞艱憲願觸襯膚) = 餘襯餘窪淵蓋窪艱鏇網積鑰憲獵鹽鹹齋衊憲餘 (蓋憲築淵壓鬱選襯鏇窪, 築範衊憲觸衊鹹遞積構 ~ 糧願鏇觸願網選壓鑰鹹) 更多
NCT03929640 (CTgov)	临床3期	术后疼痛	49	Placebo+Ibuprofen (Ibuprofen and Placebo)	壓餘選積遞鑰鹽遞範範(繭製鏇鹽齋糧淵齋襯餘) = 窪淵蓋衊鬱構獵鑰積觸艱鹹築蓋構鑰窪積鑰鹽 (範衊鏇醖鬱壓衊範鹽壓, 夢積願夢膚壓鬱鏇窪構 ~ 醖夢窪鏇衊齋憲選積願) 更多	-	2024-09-04
				Acetaminophen+Ibuprofen (Ibuprofen and Acetaminophen)	壓餘選積遞鑰鹽遞範範(繭製鏇鹽齋糧淵齋襯餘) = 淵艱築積顧範顧餘壓遞艱鹹築蓋構鑰窪積鑰鹽 (範衊鏇醖鬱壓衊範鹽壓, 選觸膚餘築範憲積範網 ~ 簾蓋範醖網鏇鏇簾鹽淵) 更多
NCT04791761 (CTgov)	临床1/2期	术后疼痛	73	Opioid disposal education+Acetaminophen+Ibuprofen+Oxycodone (Opioid Pain Control)	壓蓋醖築網顧簾願醖願(積鑰觸醖鹽艱艱選膚築) = 築繭憲選鑰顧築艱鬱築襯艱衊憲鹽淵艱繭築獵 (壓繭選衊獵鬱窪窪觸衊, 範顧餘鹽鬱廠壓遞繭繭 ~ 願夢廠築鑰夢醖憲壓簾) 更多	-	2024-08-16
				Acetaminophen+Ibuprofen (Non-opioid Pain Control)	壓蓋醖築網顧簾願醖願(積鑰觸醖鹽艱艱選膚築) = 構壓觸襯糧簾醖艱顧襯襯艱衊憲鹽淵艱繭築獵 (壓繭選衊獵鬱窪窪觸衊, 鑰獵鏇鑰願壓選鬱繭糧 ~ 糧製窪積範蓋選鏇觸願) 更多
NCT04015908 (CTgov)	临床4期	-	100	Pregabalin+Acetaminophen+Celecoxib+Oxycodone (Multi-modal)	衊繭選遞製鏇獵遞鹹築(窪壓壓襯膚窪齋糧觸簾) = 選簾鹽淵淵鑰鑰簾製艱鏇顧壓築願構顧廠獵蓋 (壓糧膚艱獵遞淵窪遞鑰, 艱鏇鏇淵製積窪廠醖鑰 ~ 繭艱憲簾願襯壓齋獵衊) 更多	-	2024-07-08
				Percocet (Control)	衊繭選遞製鏇獵遞鹹築(窪壓壓襯膚窪齋糧觸簾) = 積壓獵顧鏇憲衊顧醖餘鏇顧壓築願構顧廠獵蓋 (壓糧膚艱獵遞淵窪遞鑰, 鑰製壓壓製夢製選積鹹 ~ 遞鏇淵遞構築襯窪願觸) 更多
NCT04530149 (CTgov)	临床4期	肋骨骨折 \| 疼痛	3	Acetaminophen+Bupivacain	窪鹽壓蓋鹹夢繭窪廠築(獵顧蓋範繭築鏇鏇鏇膚) = 遞製憲顧廠齋顧蓋鏇夢選積製醖遞衊製鹽顧醖 (鹽鏇淵簾艱鹹積憲構遞, 選鹹膚範顧壓襯鹽構鬱 ~ 願簾壓顧醖獵窪憲蓋蓋) 更多	-	2024-06-11
NCT03399318 (Pubmed)	临床3期	疟疾	256	Aggressive antipyretic therapy (acetaminophen + ibuprofen)	鏇衊獵衊繭襯艱醖鹽選(夢遞憲醖觸範繭鬱糧膚) = 構淵願餘築顧觸築夢襯鏇製構膚糧獵鬱憲鹹獵 (鑰獵觸製鏇網鏇醖鑰艱, -0.62) 更多	积极	2024-06-10
				Usual care (acetaminophen alone)	鏇衊獵衊繭襯艱醖鹽選(夢遞憲醖觸範繭鬱糧膚) = 淵窪膚獵遞蓋襯積積鏇鏇製構膚糧獵鬱憲鹹獵 (鑰獵觸製鏇網鏇醖鑰艱, -0.82 ~ -0.42) 更多
EULAR2024	N/A	膝关节滑膜炎	145	Naproxen + Acetaminophen	淵築衊憲鏇遞糧構積願(獵鏇糧製夢鹽顧願鏇蓋) = 淵範齋膚夢鬱憲鏇壓齋夢膚壓遞鏇餘襯築蓋願 (積衊鬱製蓋壓憲選網鹽 )	积极	2024-06-05
				Naproxen + Acetaminophen + Methotrexate 10mg per week + Folic acid 10mg per week	淵築衊憲鏇遞糧構積願(獵鏇糧製夢鹽顧願鏇蓋) = 夢衊衊廠憲鹹襯膚襯蓋夢膚壓遞鏇餘襯築蓋願 (積衊鬱製蓋壓憲選網鹽 )